For patients who experienced rapid and significant weight reduction while taking an SGLT-2 inhibitor or a GLP-1 agonist, ALT values normalized, suggesting a beneficial effect on liver health.
Over 6 months, an 8-hour time-restricted eating plan without calorie counting produced more weight loss than did calorie restriction, while both similarly lowered A1c.
Shared decision making using a novel clinical-decision support tool led to a reduced risk for hypoglycemic events in a prospective study of 94 high-risk elderly people with type 2 diabetes.
The US Food and Drug Administration made two drug safety–related changes to the label for Ozempic, the weight-loss formulation of the GLP-1 receptor agonist semaglutide.